New Therapy Brings Lasting Improvement in Cystic Fibrosis

Cystic fibrosis is one of the most common fatal hereditary diseases worldwide. As many as 8,000 children, teens, and adults are living with the disease in Germany today. An imbalance in salt and water transport across mucosal surfaces of the body causes people with cystic fibrosis to produce thick, sticky secretions that harm organs such as the lungs, intestine and pancreas. This leads to progressive loss of lung function and shortness of breath, which still significantly lowers life expectancy despite advances in treatment. 

Two years ago, a research group headed by Charité showed that combination therapy involving three drugs — elexacaftor, tezacaftor, and ivacaftor — is effective in a large portion of patients with cystic fibrosis, a hereditary disease, meaning that the treatment noticeably improves both lung function and quality of life. Now, the team headed by Prof. Marcus Mall, who has been the lead researcher in both studies, has investigated for the first time whether this form of treatment is also helpful in the long term, meaning over a period of 12 months or more. To examine this, the researchers took a closer look at the sputum, the secretions from patients’ respiratory tracts. “In patients with cystic fibrosis, the mucus in the airways is very sticky because it doesn’t contain enough water and the mucins, the molecules that form mucus, adhere too much due to their chemical properties. This results in thick, sticky mucus, which clogs the airways, making it harder for patients to breathe and leading to chronic bacterial infection and inflammation of the lungs,” explains Mall, Director of the Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and the Christiane Herzog Cystic Fibrosis Center at Charité.

In the current study, the researchers show that a combination of elexacaftor, tezacaftor, and ivacaftor results in less viscous respiratory secretions and decreasing inflammation and bacterial infection in the lungs of cystic fibrosis patients. “What’s more, the effects lasted over the entire one-year study period. This is really important because previous medications caused a rebound in the bacterial load in the airways,” explains Dr. Simon Gräber, 

“We plan to forge ahead with our research on how to make treatments that address cystic fibrosis via the molecular defects that cause the disease — like the triple medication combination studied here — even more effective. This includes starting treatment in early childhood with the goal of preventing chronic lung changes wherever possible,” Mall notes. “Aside from that, this therapy is not available to about ten percent of our patients right now due to their genetic conditions,” Gräber ads. “That’s why we are also hard at work on research involving new molecular treatments so we can treat all people with cystic fibrosis effectively.”

The researchers are also working to advance their understanding of mucus defects in cystic fibrosis and develop new mucolytics, drugs that thin and loosen the mucus. This research could also benefit patients with common chronic inflammatory lung diseases such as asthma and COPD.

Sources:

Laura Schaupp, Annalisa Addante, Mirjam Völler, Kerstin Fentker, Aditi Kuppe, Markus Bardua, Julia Duerr, Linus Piehler, Jobst Röhmel, Stephanie Thee, Marieluise Kirchner, Matthias Ziehm, Daniel Lauster, Rainer Haag, Michael Gradzielski, Mirjam Stahl, Philipp Mertins, Sébastien Boutin, Simon Y. Graeber, Marcus A. Mall. Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor on Sputum Viscoelastic Properties, Airway Infection and Inflammation in Patients with Cystic Fibrosis. European Respiratory Journal, 2023; 2202153 DOI: 10.1183/13993003.02153-2022

Charité – Universitätsmedizin Berlin. “Triple combination therapy brings lasting improvement in cystic fibrosis.” ScienceDaily. ScienceDaily, 7 July 2023. <www.sciencedaily.com/releases/2023/07/230707111622.htm>.

Materials provided by Charité – Universitätsmedizin Berlin. Note: Content may be edited for style and length.

Images from:

Photo by Mockuo Graphics 

https://unsplash.com/photos/2WlwSXFw7Kk